jixiang liu

Mr. jixiang liu

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2020 in Journal of Molecular Cell Biology
Verified
Journal Article
Open access
PDF file
QLQuanxue Li
Quanxue Li
WDWentao Dai
Wentao Dai
JLjixiang liu
jixiang liu
QSQingqing Sang
Qingqing Sang
YLYixue Li
Yixue Li
YLYuan-Yuan Li
Yuan-Yuan Li
The implementation of cancer precision medicine requires biomarkers or signatures for predicting prognosis and therapeutic benefits. Most of current efforts in this field are paying much more attention to predictive accuracy than to molecular mechanistic interpretability. Mechanism-driven strategy has recently emerged, aiming to build signatures with both predictive power and explanatory power. Driven by this strategy, we developed a robust gene dysregulation analysis framework with machine learning algorithms, which is capable of exploring gene dysregulations underlying carcinogenesis from high-dimensional data with cooperativity and synergy between regulators and several other transcriptional regulation rules taken into consideration. We then applied the framework to a colorectal cancer (CRC) cohort from The Cancer Genome Atlas. The identified CRC-related dysregulations significantly covered known carcinogenic processes and exhibited good prognostic effect. By choosing dysregulations with greedy strategy, we built a four-dysregulation (4-DysReg) signature, which has the capability of predicting prognosis and adjuvant chemotherapy benefit. 4-DysReg has the potential to explain carcinogenesis in terms of dysfunctional transcriptional regulation. These results demonstrate that our gene dysregulation analysis framework could be used to develop predictive signature with mechanistic interpretability for cancer precision medicine, and furthermore, elucidate the mechanisms of carcinogenesis.

17 October 2023 in Molecules
Verified
Journal Article
Open access
PDF file
LLLu Liu
Lu Liu
RNRisong Na
Risong Na
YLYang Lianjuan
Yang Lianjuan
JLjixiang liu
jixiang liu
YTYingjia Tan
Yingjia Tan
Xuecheng ChenXuecheng Chen
Xuecheng Chen
The drug development process suffers from low success rates and requires expensive and time-consuming procedures. The traditional one drug–one target paradigm is often inadequate to treat multifactorial diseases. Multitarget drugs may potentially address problems such as adverse reactions to drugs. With the aim to discover a multitarget potential inhibitor for B-cell lymphoma treatment, herein, we developed a general pipeline combining machine learning, the interpretable model SHapley Additive exPlanation (SHAP), and molecular dynamics simulations to predict active compounds and fragments. Bruton’s tyrosine kinase (BTK) and Janus kinase 3 (JAK3) are popular synergistic targets for B-cell lymphoma. We used this pipeline approach to identify prospective potential dual inhibitors from a natural product database and screened three candidate inhibitors with acceptable drug absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties. Ultimately, the compound CNP0266747 with specialized binding conformations that exhibited potential binding free energy against BTK and JAK3 was selected as the optimum choice. Furthermore, we also identified key residues and fingerprint features of this dual-target inhibitor of BTK and JAK3.

14 November 2023 in Physical Chemistry Chemical Physics
Verified
Journal Article
Closed access
PDF file
JLjixiang liu
jixiang liu
RNRi-Song Na
Ri-Song Na
LYLian-Juan Yang
Lian-Juan Yang
XHXu-Ri Huang
Xu-Ri Huang
XZXi Zhao
Xi Zhao
Six small molecules from virtual screening hits may treat neurodegenerative diseases and SARS-CoV-2 by inhibiting RIPK1.

3 April 2020 in Journal of Molecular Cell Biology
Verified
Journal Article
Open access
PDF file
JLjixiang liu
jixiang liu
WLWei Liu
Wei Liu
XLXueling Li
Xueling Li
QLQuanxue Li
Quanxue Li
WDWentao Dai
Wentao Dai
YLYuanyuan Li
Yuanyuan Li
With the increasing use of high-throughput sequencing technology in tumor research, a large number of somatic variations are being identified and some of them have proved to be responsible for tumorigenesis ( Cancer Genome Atlas Research Network et al., 2013). Investigating structural and functional impacts of tumor somatic variants would greatly help to identify causal variations, understand the mechanisms of carcinogenesis, and develop novel anti-tumor therapies. Therefore, many efforts have recently been made to map genomic variations to 3D protein structure, such as G23D ( Solomon et al., 2016) and G2S ( Wang et al., 2018). Furthermore, Cancer 3D database ( Porta-Pardo et al., 2015) and HotSpot3D ( Niu et al., 2016) were developed to discover functional implications of mutations by means of structure data and drug information. However, there are still some limitations. Firstly, the effects of insertions and deletions (indels) are not taken into consideration. Secondly, these tools heavily depend on the resolved structures in Protein Data Bank (PDB) ( Berman et al., 2000), i.e. they are not applicable when there is no reliable structural information available for wild-type protein. Here, we developed a webserver, TGPred, which provides a series of functionalities, including protein structure prediction, ligand binding site prediction, identification of functional relevant mutations, and estimation of functional impacts of mutations. Based on an interactive visualization design, these analyses are flexibly integrated, and thus the function impacts of a given protein variant could be inferred. The website is available at http://www.yyli-lab.cn/TGPred/.

9 December 2024 in Physical Chemistry Chemical Physics
Verified
Journal Article
Closed access
PDF file
LLLu Liu
Lu Liu
JLjixiang liu
jixiang liu
LCLiang Chen
Liang Chen
RNRisong Na
Risong Na
YLYang Lianjuan
Yang Lianjuan
XZXi Zhao
Xi Zhao
TWIK-related acid-sensitive potassium channel 1 (TASK-1) is expressed ubiquitously across various tissues and plays a significant role in neural activity and anesthetic modulation, making it a crucial target for pharmaceutical research. The high conservation of binding site residues within the TASK family, particularly between TASK-1 and TASK-3, necessitates the development of selective inhibitors for TASK-1. In this study, we utilized a combination of structure-based drug design (SBDD) and ligand-based drug design (LBDD) approaches. Initially, several bisamide-centered molecules were designed using the program MolAICal, which is recognized for its ability to generate selective inhibitors containing bisamide segments, and conducted preliminary screening via molecular docking. Subsequently, 3D-QSAR models were developed for 56 bisamide derivatives targeting TASK-1 and TASK-3, with the models exhibiting robust predictive capabilities (TASK-1: Q2 = 0.61, R2 pred = 0.84; TASK-3: Q2 = 0.60, R2 pred = 0.71). Using these models, the candidate molecules were subjected to activity prediction and subsequent filtering. Ultimately, molecular dynamics simulations, coupled with free energy calculations, pinpointed two bisamide-core molecules with favorable ADMET properties as potential selective inhibitors for TASK-1. Furthermore, molecular dynamics simulations revealed the critical role of the key residue Leu122 in conferring selectivity to bisamide compounds for TASK-1 channel proteins.